This includes the capture of tau phosphorylated at threonine 181 (pT181-tau) and threonine 217 (pT217-tau), tau species used as fluid-based biomarkers in humans, where pT217-tau in particular is being developed as a plasma biomarker for incipient AD (Barthelemy et al., 2020; Hansson et al., 2023; Janelidze et al., 2020; Mattsson-Carlgren et al., 2023; Olsson et al., 2016; Salvado et al., 2023). Here, MAPT is linked to Alzheimer disease.